17-alpha hydroxyprogesterone caproate and risk for venous thromboembolism during pregnancy

Schuster, Meike; Ananth, Cande V.; Gómez, Daniela; Huang, Yongmei; Gyamfi-Bannerman, Cynthia; Wright, Jason D.; D’Alton, Mary E.; Friedman, Alexander M.

doi:10.1080/14767058.2021.1911997

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These differences between the compounds underlie the potential differences in clinical indications as well as the potential differences in side effects. 10 The large IBM MarketScan® Commercial Claims and Encounters Database has served in recent years as a powerful tool for investigating the potential associations between myriad exposures during pregnancy and various complications 11,12 as well as for better understanding patterns of prescription 13 . In the current study, we sought to leverage the claims and encounters database to investigate the association between second and third trimester progestogens therapy and ICP in singleton pregnancies.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Vaginal Progesterone Is Associated with Intrahepatic Cholestasis of Pregnancy

et al. 2023

View full text Add to dashboard Cite

Background The frequency of intrahepatic cholestasis of pregnancy peaks during the third trimester of pregnancy when plasma progesterone levels are highest. Furthermore, twin pregnancies are characterized by higher progesterone levels than singletons, and have a higher frequency of cholestasis. Therefore, we hypothesized that exogenous progestogens administered for reducing the risk of spontaneous preterm birth may increase the risk of cholestasis. Objectives Utilizing the large IBM MarketScan® Commercial Claims and Encounters Database, we investigated the frequency of cholestasis in patients treated with vaginal progesterone or intramuscular 17α-hydroxyprogesterone caproate for the prevention of preterm birth. Study design We identified 1,776,092 live-born singleton pregnancies between 2010-2014. We confirmed 2nd and 3rd trimester administration of progestogens by cross-referencing the dates of progesterone prescriptions with the dates of scheduled pregnancy events such as nuchal translucency scan, fetal anatomy scan, glucose challenge test, and Tdap vaccination. We excluded pregnancies with missing data regarding timing of scheduled pregnancy events, or progesterone treatment prescribed only during the 1st trimester. Cholestasis of pregnancy was identified based on prescriptions for ursodeoxycholic acid. We used multivariable logistic regression to estimate adjusted (for maternal age) odds ratios for cholestasis in patients treated with vaginal progesterone, and in patients treated with 17α-hydroxyprogesterone caproate compared to those not treated with any type of progestogen (the reference group). Results The final cohort consisted of 870,599 pregnancies. Among patients treated with vaginal progesterone during the 2nd and 3rd trimester, the frequency of cholestasis was significantly higher than the reference group (0.75% vs 0.23%, aOR 3.16, 95% CI 2.23-4.49). In contrast, there was no significant association between 17α-hydroxyprogesterone caproate and cholestasis (0.27%, aOR 1.12, 95% CI 0.58-2.16) Conclusions Using a robust dataset, we observed that vaginal progesterone but not intramuscular 17α-hydroxyprogesterone caproate was associated with an increased risk for intrahepatic cholestasis of pregnancy.

show abstract